Peer-Reviewed Publication
Sci Transl Med2026;18(871):eaef8416.October 14, 2026Journal Article
Innovative roadmaps for sustainable antimicrobial resistance interventions.
Gianmarco Gasperini1, Silvia Rossi Paccani1, Karen O'Dwyer2, David M Aanensen3, Darius Armstrong-James4, Francesco Berlanda Scorza1, David E Bloom5, Christopher J Burns6, Madalina Elena Carter-Timofte7, Felipe J Colón-González8, Shampa Das9, Michael N Dudley10, Philippe Denoel11, Gordon Dougan12, Erin M Duffy13, Alison Holmes14, Anders Karlén15, Neil Pearson2, Rosanna Ŵ Peeling16, Jesus Rodriguez-Manzano4,14, J P Sevilla17,18, Shiranee Sriskandan4,19, Sumithra Subramaniam8, Herbert W Virgin13,20, Rino Rappuoli21, David Payne2, Ennio De Gregorio1
1GSK, Siena, Italy.
2GSK, Upper Providence, PA, USA.
3Centre for Genomic Pathogen Surveillance, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
4Department of Infectious Disease, Faculty of Medicine, Imperial College, London, UK.
5Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
6BBC Pharma Advisors, Malvern, PA, USA.
7Novo Nordisk Foundation, Hellerup, Denmark.
8Data for Science and Health, Wellcome Trust, London, UK.
9Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
10Qpex Biopharma Inc., San Diego, CA, USA.
11GSK, Rixensart, Belgium.
12Department of Medicine, University of Cambridge, Cambridge, UK.
13Gates Foundation, Seattle, WA, USA.
14Fleming Initiative, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
15Department of Medicinal Chemistry, BMC, Uppsala University, Uppsala, Sweden.
16London School of Hygiene and Tropical Medicine, London, UK.
17Data for Decisions LLC, Boston, MA, USA.
18T. H. Chan School of Public Health, Boston, MA, USA.
19Centre for Bacterial Resistance Biology, Imperial College London, London, UK.
20Washington University School of Medicine, Saint Louis, MO, USA.
21Fondazione Biotecnopolo di Siena, Siena, Italy.
Abstract
Integrated strategies to combat antibiotic-resistant bacteria and fungi require innovative commercial models, new discovery platforms, standardized genomic surveillance, and streamlined clinical trials. Machine learning and other new technologies will accelerate the development of diagnostics and therapeutics (small molecules, antibodies, and vaccines) to combat antimicrobial resistance. Next-gene…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans